Novartis has inked a deal with Sironax that gives the pharma the exclusive option to acquire the biotech’s blood-brain ...

Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis under ...

Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

BDS has performed consultancies for Roche, Eisai, EQTpartners, Remynd, Tactile, Earlybird, Sironax, Montis, and Abyssinia; and is a shareholder of Muna Tx. CH collaborates with Denali Therapeutics and ...

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for GSK in ...

Li-Xuan Qin Employment: Sironax (I) Leadership: Sironax (I) Stock and Other Ownership Interests: Sironax Mithat Gonen Travel, Accommodations, Expenses: Genentech Andrea Cercek ...

SIR-2501 is under clinical development by Sironax and currently in Phase I for Neurodegenerative Diseases.

SIR-2501 is under clinical development by Sironax and currently in Phase I for Neuropathy. According to GlobalData, Phase I drugs for Neuropathy have an 88% phase transition success rate (PTSR) ...

LaingBuisson has been serving clients for over 30 years with insights, analysis and data on market structures, policy and strategy across healthcare, social care and education ...